文献速递造血干细胞移植与细胞治疗

pp65特异性TCR-T细胞治疗造血干细胞移植后巨细胞病毒感染的效果

Efficacy of pp65-specific TCR-T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation.
PubMed 文献 · Am J Hematol · 2022-09-22

本研究从健康供者中筛选巨细胞病毒(CMV)抗原特异性TCR并构建靶向多个pp65表位的TCR-T细胞,体外实验显示对表达表位的靶细胞有细胞毒性,免疫缺陷小鼠体内诱导肿瘤消退并长期存续。I期临床试验(NCT04153279)治疗造血干细胞移植后CMV再激活患者,除1例早期退出外,其余6例耐受良好并均达完全缓解(CR),仅观察到不超过2级细胞因子释放综合征(CRS)及其他不良事件,TCR-T细胞持续长达3个月,其中2例患者生存超过1年。

要点

  • 靶向多个pp65表位的TCR-T细胞在体外对表达表位的靶细胞有细胞毒性。
  • I期试验中6例可评估患者均达完全缓解(CR),仅见不超过2级CRS及其他不良事件。
  • CMV TCR-T细胞持续长达3个月,2例患者生存超过1年。

核心结论

  • 本研究显示CMV TCR-T细胞在治疗造血干细胞移植后CMV感染方面具有较大潜力,并可能用于其他器官移植后CMV感染的防治。

研究设计与样本

  • 临床前研究:利用四聚体筛选和单细胞TCR克隆技术从健康供者中鉴定CMV抗原特异性TCR,构建靶向三个主要HLA-A等位基因对应多个pp65表位的TCR-T细胞。
  • 体内实验:将TCR-T细胞转移至荷pp65+ HLA+肿瘤细胞的免疫缺陷小鼠。
  • I期临床试验(NCT04153279):将CMV TCR-T细胞用于治疗造血干细胞移植后CMV再激活患者。

主要发现

  • 体外实验:TCR-T细胞对表达表位的靶细胞表现出有效的细胞毒性。
  • 小鼠实验:TCR-T细胞转移后诱导显著的肿瘤消退并表现出长期存续。
  • 临床试验:除1例患者在治疗早期退出外,其余6例患者耐受良好并均达到完全缓解(CR),仅观察到不超过2级细胞因子释放综合征(CRS)及其他不良事件。
  • CMV TCR-T细胞持续长达3个月,其中2例患者生存超过1年。

临床怎么用

  • 作者认为本研究展示了CMV TCR-T细胞在造血干细胞移植后或其他器官移植后CMV感染治疗与预防方面的较大潜力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytomegalovirus (CMV) infection remains a major cause of mortality after hematopoietic stem cell transplantation (HSCT). Current treatments, including antiviral drugs and adoptive cell therapy with CMV-specific cytotoxic T lymphocytes (CTLs), only show limited benefits in patients. T-cell receptor (TCR)-T cell therapy offers a promising option to treat CMV infections. Here, using tetramer-based screening and single-cell TCR cloning technologies, we identified various CMV antigen-specific TCRs from healthy donors, and generated TCR-T cells targeting multiple pp65 epitopes corresponding to three major HLA-A alleles. The TCR-T cells showed efficient cytotoxicity toward epitope-expressing target cells in vitro. After transfer into immune-deficient mice bearing pp65+ HLA+ tumor cells, TCR-T cells induced dramatic tumor regression and exhibited long-term persistence. In a phase I clinical trial (NCT04153279), CMV TCR-T cells were applied to treat patients with CMV reactivation after HSCT. Except one patient who withdrew at early treatment stage, all other six patients were well-tolerated and achieved complete response (CR), no more than grade 2 cytokine release syndrome (CRS) and other adverse events were observed. CMV TCR-T cells persisted up to 3 months. Among them, two patients have survived for more than 1 year. This study demonstrates the great potential in the treatment and prevention of CMV infection following HSCT or other organ transplantation.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Liu G, Chen H, Cao X, et al. Efficacy of pp65-specific TCR-T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation. Am J Hematol. 2022. PMID: 36054234. doi:10.1002/ajh.26708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。